143 related articles for article (PubMed ID: 37060201)
21. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
22. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
[TBL] [Abstract][Full Text] [Related]
23. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
[TBL] [Abstract][Full Text] [Related]
24. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
25. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Schiewer MJ; Knudsen KE
Urol Clin North Am; 2021 Aug; 48(3):339-347. PubMed ID: 34210489
[TBL] [Abstract][Full Text] [Related]
26. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
27. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
[TBL] [Abstract][Full Text] [Related]
28. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
29. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
30. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells.
Bühler P; Wolf P; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Freudenberg N; Elsässer-Beile U
Oncol Rep; 2010 Feb; 23(2):465-70. PubMed ID: 20043108
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Lapointe J; Li C; Higgins JP; van de Rijn M; Bair E; Montgomery K; Ferrari M; Egevad L; Rayford W; Bergerheim U; Ekman P; DeMarzo AM; Tibshirani R; Botstein D; Brown PO; Brooks JD; Pollack JR
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):811-6. PubMed ID: 14711987
[TBL] [Abstract][Full Text] [Related]
32. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
33. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.
You S; Knudsen BS; Erho N; Alshalalfa M; Takhar M; Al-Deen Ashab H; Davicioni E; Karnes RJ; Klein EA; Den RB; Ross AE; Schaeffer EM; Garraway IP; Kim J; Freeman MR
Cancer Res; 2016 Sep; 76(17):4948-58. PubMed ID: 27302169
[TBL] [Abstract][Full Text] [Related]
34. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
35. Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.
Heemers HV; Schmidt LJ; Sun Z; Regan KM; Anderson SK; Duncan K; Wang D; Liu S; Ballman KV; Tindall DJ
Cancer Res; 2011 Mar; 71(5):1978-88. PubMed ID: 21324924
[TBL] [Abstract][Full Text] [Related]
36. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.
Li QK; Chen J; Hu Y; Höti N; Lih TM; Thomas SN; Chen L; Roy S; Meeker A; Shah P; Chen L; Bova GS; Zhang B; Zhang H
Sci Rep; 2021 Sep; 11(1):18936. PubMed ID: 34556748
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
38. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
[TBL] [Abstract][Full Text] [Related]
39. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
40. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
